Professor Dr. P.H. Nibbering from the Department of Infectious Diseases – UMC Leiden (LUMC) has received an NWO grant entitled: Next stage development of the novel synthetic antimicrobial peptide SAAP-148 (NESDAP). The project focuses on the development of a synthetic peptide for topical wound treatment, in response to growing concern for untreatable infections, due to antimicrobial resistance. Together with LUMC and other project partners involved, Avivia will perform several parallel development tests, using nanoparticles and PLGA microspheres, to optimize the delivery of SAAP-148 deep into wounds with a controlled release over time.
Next stage development of the novel synthetic antimicrobial peptide SAAP-148 (NESDAP) – NWO TTW grant
The emergence of antimicrobial resistance (AMR) worldwide raises fears of untreatable infections. It has been estimated that 10 million people will be dying as a result of AMR in 2050 and associated costs will amount to $100 trillion. In an attempt to prevent this dark scenario we have developed a novel agent, i.e. the synthetic antibacterial and anti-biofilm peptide (SAAP)-148, that is highly effective against AMR bacteria and biofilms. In this project we will develop chemical modifications to increase peptide’s stability and ability to penetrate cells, while minimizing its side effects. Several strategies, e.g. nanoparticles and PLGA microspheres, to optimize the delivery of SAAP-148 deep into wounds with a controlled release over time will be developed in parallel. Efficacy of combinations of optimal formulations and SAAP-148 will be investigated in animal models for chronic wound infections. Successful combinations will be available for clinical trials.
December 19, 2017
M-building – Novio Tech Campus
6534 AT Nijmegen, The Netherlands
Email info [at] avivia.nl
Phone - Reception +31 (0)6-1968-6732